MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study

Archives of Gerontology and Geriatrics

Volumn 53, Issue 2, 2011, Pages 183-189

  Adunsky, Abraham ^a   Chandler, Julie ^b   Heyden, Norman ^b   Lutkiewicz, Jeannine ^b   Scott, Boyd B ^b   Berd, Yuliya ^b   Liu, Nancy ^b   Papanicolaou, Dimitris A ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Disability; Ghrelin receptor; Growth hormone; Hip fracture; IGF 1; Sarcopenia

Indexed keywords

IBUTAMOREN; PLACEBO; SOMATOMEDIN C;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD DISEASE; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FALLING; FEMALE; FUNCTIONAL ASSESSMENT; GAIT; GLUCOSE BLOOD LEVEL; HEART DISEASE; HIP FRACTURE; HUMAN; INFECTION; INFESTATION; INJURY; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; THORAX DISEASE; URINARY TRACT DISEASE; VASCULAR DISEASE; WALKING SPEED; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FRACTURE HEALING; HIP FRACTURES; HUMANS; INDOLES; LOWER EXTREMITY; MALE; MIDDLE AGED; MUSCLE STRENGTH; PHYSICAL THERAPY MODALITIES; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; RECOVERY OF FUNCTION; SPIRO COMPOUNDS; TREATMENT OUTCOME;

EID: 79960083206     PISSN: 01674943     EISSN: 18726976     Source Type: Journal    
DOI: 10.1016/j.archger.2010.10.004     Document Type: Article

References (37)

1. Bach M.A., Rockwood K., Zetterberg C., Thamsborg G., Hebert R., Devogelaer J.P., Christiansen J.S., Rizzoli R., Ochsner J.L., Beisaw N., Gluck O., Yu L., Schwab T., Farrington J., Taylor A.M., Ng J., Fuh V. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J. Am. Geriatr. Soc. 2004, 52:516-523.
2. Baumgartner R.N., Koehler K.M., Gallagher D., Romero L., Heymsfield S.B., Ross R.R., Garry P.J., Lindeman R.D. Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol. 1998, 147:755-763.
3. Bean J.F., Kiely D.K., LaRose S., Alian J., Frontera W.R. Is stair climb power a clinically relevant measure of leg power impairments in at-risk older adults?. Arch. Phys. Med. Rehabil. 2007, 88:604-609.
4. Borst S.E. Interventions for sarcopenia and muscle weakness in older people. Age Ageing 2004, 33:548-555.
5. Chapman I.M., Bach M.A., Van Cauter E., Farmer M., Krupa D., Taylor A.M., Schilling L.M., Cole K.Y., Skiles E.H., Pezzoli S.S., Hartman M.L., Veldhuis J.D., Gormley G.J., Thorner M.O. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J. Clin. Endocrinol. Metab. 1996, 81:4249-4257.
6. Cress M.E., Buchner D.M., Questad K.A., Esselman P.C., deLateur B.J., Schwartz R.S. Exercise: effects on physical functional performance in independent older adults. J. Gerontol. A: Biol. Sci. Med. Sci. 1999, 54:M242-M248.
7. Cress M.E., Petrella J.K., Moore T.L., Schenkman M.L. Continuous-scale physical functional performance test: validity, reliability, and sensitivity of data for the short version. Phys. Ther. 2005, 85:323-335.
8. Eastwood E.A., Magaziner J., Wang J., Silberzweig S.B., Hannan E.L., Strauss E., Siu A.L. Patients with hip fracture: subgroups and their outcomes. J. Am. Geriatr. Soc. 2002, 50:1240-1249.
9. Ferrucci L., Guralnik J.M., Studenski S., Fried L.P., Cutler, Walston J.D. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J. Am. Geriatr. Soc. 2004, 52:625-634.
10. Fiatarone-Singh M.A., Singh N.A., Hansen R.D., Finnegan T.P., Allen B.J., Diamond T.H., Diwan A.D., Lloyd B.D., Williamson D.A., Smith E.U., Grady J.N., Stavrinos T.M., Thompson M.W. Methodology and baseline characteristics for the sarcopenia and hip fracture study: a 5-year prospective study. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64:568-574.
11. Greenlund L.J., Nair K.S. Sarcopenia - consequences, mechanisms, and potential therapies. Mech. Ageing Dev. 2003, 124:287-299.
12. Gullberg B., Johnell O., Kanis J.A. World-wide projections for hip fracture. Osteoporos. Int. 1997, 7:407-413.
13. Guralnik J.M., Simonsick E.M., Ferrucci L., Glynn R.J., Berkman L.F., Blazer D.G., Scherr P.A., Wallace R.B. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J. Gerontol. 1994, 49:M85-M94.
14. Haley S.M., Coster W.J., Andres P.L., Kosinski M., Ni P. Score comparability of short forms and computerized adaptive testing: Simulation study with the activity measure for post-acute care. Arch. Phys. Med. Rehabil. 2004, 85:661-666.
15. Haley S.M., Coster W.J., Andres P.L., Ludlow L.H., Ni P., Bond T.L., Sinclair S.J., Jette A.M. Activity outcome measurement for postacute care. Med. Care 2004, 42:149-161.
16. Handoll H.H., Cameron I.D., Mak J.C., Finnegan T.P. Multidisciplinary rehabilitation for older people with hip fractures. Cochrane. Database. Syst. Rev. 2009, CD007125.
17. Janssen I., Heymsfield S.B., Wang Z.M., Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J. Appl. Physiol. 2000, 89:81-88.
18. Jette A.M., Tao W., Norweg A., Haley S. Interpreting rehabilitation outcome measurements. J. Rehabil. Med. 2007, 39:585-590.
19. Johnson M.F., Kramer A.M., Lin M.K., Kowalsky J.C., Steiner J.F. Outcomes of older persons receiving rehabilitation for medical and surgical conditions compared with hip fracture and stroke. J. Am. Geriatr. Soc. 2000, 48:1389-1397.
20. Latham N.K., Mehta V., Nguyen A.M., Jette A.M., Olarsch S., Papanicolaou D., Chandler J. Performance-based or self-report measures of physical function: which should be used in clinical trials of hip fracture patients?. Arch. Phys. Med. Rehabil. 2008, 89:2146-2155.
21. Lynch G.S. Update on emerging drugs for sarcopenia - age-related muscle wasting. Expert. Opin. Emerg. Drugs 2008, 13:655-673.
22. Marottoli R.A., Berkman L.F., Cooney L.M. Decline in physical function following hip fracture. J. Am. Geriatr. Soc. 1992, 40:861-866.
23. McHorney C.A., Ware J.E., Raczek A.E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 1993, 31:247-263.
24. Nagi S.Z. An epidemiology of disability among adults in the United States. Milbank Membr. Fund. Q. Health Soc. 1976, 54:439-467.
25. Newman A.B., Kupelian V., Visser M., Simonsick E.M., Goodpaster B.H., Kritchevsky S.B., Tylavsky F.A., Rubin S.M., Harris T.B. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A: Biol. Sci. Med. Sci. 2006, 61:72-77.
26. Palombaro K.M., Craik R.L., Mangione K.K., Tomlinson J.D. Determining meaningful changes in gait speed after hip fracture. Phys. Ther. 2006, 86:809-816.
27. Penninx B.W., Ferrucci L., Leveille S.G., Rantanen T., Pahor M., Guralnik J.M. Lower extremity performance in nondisabled older persons as a predictor of subsequent hospitalization. J. Gerontol. A: Biol. Sci. Med. Sci. 2000, 55:M691-M697.
28. Perera S., Mody S.H., Woodman R.C., Studenski S.A. Meaningful change and responsiveness in common physical performance measures in older adults. J. Am. Geriatr. Soc. 2006, 54:743-749.
29. Roubenoff R., Hughes V.A. Sarcopenia: current concepts. J. Gerontol. A: Biol. Sci. Med. Sci. 2000, 55:M716-M724.
30. Ryall J.G., Schertzer J.D., Lynch G.S. Cellular and molecular mechanisms underlying age-related skeletal muscle wasting and weakness. Biogerontology 2008, 9:213-228.
31. Sherrington C., Lord S.R. Reliability of simple portable tests of physical performance in older people after hip fracture. Clin. Rehabil. 2005, 19:496-504.
32. Smith R.G., Sun Y., Betancourt L., Asnicar M. Growth hormone secretagogues: prospects and potential pitfalls. Best. Pract. Res. Clin. Endocrinol. Metab. 2004, 18:333-347.
33. Suzuki T., Bean J.F., Fielding R.A. Muscle power of the ankle flexors predicts functional performance in community-dwelling older women. J. Am. Geriatr. Soc. 2001, 49:1161-1167.
34. Thorner M.O. Statement by the Growth Hormone Research Society on the GH/IGF-I axis in extending health span. J. Gerontol. A: Biol. Sci. Med. Sci. 2009, 64:1039-1044.
35. Verbrugge L.M., Jette A.M. The disablement process. Soc. Sci. Med. 1994, 38:1-14.
36. White H.K., Petrie C.D., Landschulz W., MacLean D., Taylor A., Lyles K., Wei J.Y., Hoffman A.R., Salvatori R., Ettinger M.P., Morey M.C., Blackman M.R., Merriam G.R. Effects of an oral growth hormone secretagogue in older adults. J. Clin. Endocrinol. Metab. 2009, 94:1198-1206.
37. Zadik Z., Chalew S.A., McCarter R.J., Meistas M., Kowarski A.A. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J. Clin. Endocrinol. Metab. 1985, 60:513-516.